Myqorzo (Aficamten)

Aficamten is a medicine for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and squeezes too hard. It works by calming the heart muscle so blood can flow out more easily. It's taken as a pill.

Brand names:Myqorzo
Medication

What people taking Myqorzo (Aficamten) report

Every report comes from a Lived member, sent anonymously.

Have you tried Myqorzo (Aficamten) for HCM (Hypertrophic Cardiomyopathy)?

NameHow it went

About Myqorzo (Aficamten)

What It's For

Aficamten, sold as Myqorzo, is a prescription tablet for adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM). It is approved to improve how well people can exercise and carry out daily activity, and to ease symptoms. The US Food and Drug Administration (FDA) approved it in 2025. In HCM, the wall of the heart's main pumping chamber (the left ventricle) becomes abnormally thick. In the obstructive form, the thickened muscle partly blocks blood as it leaves the heart, especially during exertion. That blockage is a common reason people feel breathless, tired, light-headed or have chest discomfort when they are active. Aficamten is a cardiac myosin inhibitor, a drug class aimed at the overactive heart muscle that drives HCM. It is the second medicine of this type in the US, after mavacamten (Camzyos). Beta-blockers remain the usual first treatment in current guidelines, and most people in aficamten's main study were already taking one, but a head-to-head trial found aficamten on its own improved exercise measures more than the beta-blocker metoprolol. Aficamten is not approved for children or for the non-obstructive form of HCM.

How It Works

Heart muscle contracts when a motor protein called myosin pulls on neighboring protein fibers. In HCM, the muscle tends to squeeze harder than the body needs, which contributes to the thickened wall pressing into the path blood takes out of the heart. Aficamten binds to cardiac myosin and reversibly reduces the force it generates. The heart still pumps normally for most people, but with less excess squeeze, so the outflow path stays more open. Doctors track this on an echocardiogram (a heart ultrasound) as the outflow gradient, the pressure difference blood has to push through to leave the heart. A gradient of 30 mmHg or more signals meaningful obstruction. In the main trial, about half of people taking aficamten brought their gradient below 30 during a straining maneuver, compared with about 4% on placebo. The same effect explains the drug's main risk. If the squeeze is reduced too far, the heart can pump too weakly, which is why the dose is set by repeated heart scans rather than by a fixed schedule.

Dosage & Administration

Aficamten is taken by mouth once a day, at about the same time each day, with or without food. The tablet is swallowed whole. Treatment starts at 5 mg. Every 2 to 8 weeks, the cardiologist checks an echocardiogram and may raise the dose in 5 mg steps, up to a maximum of 20 mg. Two numbers guide each decision. The outflow gradient shows whether obstruction is still present. The ejection fraction (LVEF) is the percentage of blood the left ventricle pumps out with each beat; people with HCM often start around 75%. Aficamten is not started if the LVEF is below 55%, the dose is lowered if it falls below 50%, and treatment is paused if it drops below 40%. Once a steady dose is found, scans usually continue every 6 months, or every 3 months if the LVEF sits just above 50%. Because of the heart failure risk, Myqorzo is available only through a restricted safety program (the Myqorzo REMS). The prescriber, the patient and the pharmacy must all be enrolled, and the patient agrees to keep up with the scans. If a dose is missed, take it later the same day if possible; never take two doses on the same day.

Side Effects

The most common side effect in the main trial was higher blood pressure, reported in 8% of people on aficamten compared with 2% on placebo. This likely reflects better blood flow out of the heart once the obstruction eases, but readings that run noticeably higher are worth raising with the care team. The serious risk is heart failure from the heart pumping too weakly. In the 24-week trial, 4% of people on aficamten had their ejection fraction drop below 50%; in those cases it recovered and did not cause heart failure symptoms, but monitoring is designed to catch this early. Contact the prescriber or get medical help right away for new or worsening shortness of breath, swelling in the legs, a racing or irregular heartbeat, unusual fatigue, chest pain or rapid weight gain. Some of these overlap with HCM symptoms, so a change from your usual pattern is what matters.

Interactions & Warnings

Aficamten carries the FDA's most prominent warning, a boxed warning, because it lowers the heart's pumping strength and can cause heart failure. That is the reason for the echocardiograms before and during treatment and the restricted distribution program. Several medicines change how much aficamten stays in the blood, which can tip the balance toward heart failure or toward losing the benefit. Rifampin, an antibiotic used mainly for tuberculosis, must not be taken with aficamten because it sharply lowers its level. Starting the antifungal fluconazole for more than 3 days, the antifungal voriconazole, or fluvoxamine (an antidepressant used for obsessive-compulsive disorder) can raise aficamten levels; the dose may need to be cut or the combination avoided. Stopping some medicines that speed aficamten's breakdown, such as the seizure medicine carbamazepine, can have the same effect. Tell the cardiologist and pharmacist before starting or stopping any medicine, including over-the-counter products and supplements. A serious illness such as a significant infection, or a new or worsening irregular heartbeat such as atrial fibrillation, raises the chance of heart failure while on aficamten. Let the care team know, since the dose may be lowered or paused until you recover. There is no human information on aficamten in pregnancy, and animal studies showed birth defects at exposures above the highest human dose. Tell the prescriber if you are pregnant or planning to be, or if pregnancy occurs during treatment or within 3 weeks after the last dose. Whether aficamten passes into breast milk is not known.

What to Expect

The first months involve frequent visits and scans while the dose is adjusted. In the main trial, many people noticed improvement within 12 weeks. By 24 weeks, about 58% had moved up at least one level on the standard heart symptom scale, for example from breathless with ordinary activity to breathless only with more than ordinary effort, compared with about 24% on placebo. Exercise capacity measured on a treadmill or bike also improved, and people spent far fewer days with symptoms severe enough to qualify for septal reduction therapy, a surgery or catheter procedure that removes or shrinks the thickened muscle. Not everyone responds, and the improvement is in symptoms and activity rather than a cure for HCM. The effect is reversible: about 4 weeks after the trial ended, ejection fraction and blood pressure were similar to placebo again, so benefit is expected to last only while the medicine is taken. The main trial lasted 24 weeks, and longer-term results, including any effect on survival or later need for procedures, are still being studied. Ongoing scans every few months remain part of treatment for as long as you take it.

Questions to Ask Your Doctor

  1. 1.Would aficamten, mavacamten or adjusting my current beta-blocker or calcium channel blocker make the most sense for my symptoms?
  2. 2.What gradient and ejection fraction results are we aiming for, and how often will I need echocardiograms?
  3. 3.Which of my current medicines or supplements could interact with aficamten, and what should I do if another doctor prescribes something new?
  4. 4.If I get a serious infection or my heart rhythm changes, should I keep taking it or call you first?
  5. 5.How will we decide whether it is working well enough, and would septal reduction therapy still be an option for me?

Last reviewed • Oct 2026

Educational content, not medical advice.